Inflammation in neurological and psychiatric diseases

Inflammopharmacology

Volumn 20, Issue 3, 2012, Pages 103-107

  Khansari, Parto S ^a   Sperlagh, Beata ^b  

^a CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Acute neurological diseases; Alzheimer's disease; Astrocytes; Chronic neurological diseases; Major depression; Microglia; Neuroinflammation; NSAIDs; Parkinson's disease; Pro inflammatory cytokines; Psychiatric diseases; Schizophrenia; Stroke

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; EXCITATORY AMINO ACID TRANSPORTER 2; GAMMA INTERFERON; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADJUVANT THERAPY; ALZHEIMER DISEASE; ANHEDONIA; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CHRONIC INFLAMMATION; CYTOKINE RESPONSE; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; EMOTION; FEELING OF WORTHLESSNESS; GUILT; HUMAN; LEWY BODY; MAJOR DEPRESSION; MICROGLIA; MOOD DISORDER; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT;

ANIMALS; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES;

EID: 84862978546     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-012-0124-x     Document Type: Article

References (70)

1. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B et al (2007) Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90:179-185
2. Aktas O, Ullrich O, Infante-Duarte C, Nitsch R, Zipp F (2007) Neuronal damage in brain inflammation. Arch Neurol 64(2):185-189
3. Allan SM, Rothwell NJ (2003) Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci 358(1438): 1669-1677
4. Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, Babulas VP, Susser ES (2004) Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatr 61:774-780
5. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH (2001) Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 58(11):1032-1037
6. Capuron L, Fornwalt FB, Knight BT, Harvey PD, Ninan PT, Miller AH (2009) Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord 119(1-3):181-185
7. Catena-Dell'Osso M, Bellantuono C, Consoli G, Baroni S, Rotella F, Marazziti D (2011) Inflammatory and neurodegenerative path-waysindepression: a new avenue for antidepressant development? Curr Med Chem 18(2):245-255
8. Chakraborty S, Kaushik DK, Gupta M, Basu A (2010) Inflammasome signaling at the heart of central nervous system pathology. J Neurosci Res 88(8):1615-1631
9. Creed F, Dickens C (2007) Depression in the medically ill. In: Steptoe A (ed) Depression and physical illness. Cambridge University Press, Cambridge, pp 3-18
10. Członkowska A, Kurkowska-Jastrzȩbska I (2011) Inflammation and gliosis in neurological diseases-clinical implications. J Neuro-immunol 231(1-2):78-85
11. Dantzer R, Kelley KW (2007) Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 21:153-160
12. Dhabhar FS, Burke HM, Epel ES, Mellon SH, Rosser R, Reus VI, Wolkowitz OM (2009) Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. Psychiatr Res 43(11):962-969
13. Dickens C, McGowan L, Percival C, Tomenson B, Cotter L, Heagerty A, Creed F (2007) Depression is a risk factor for mortality after myocardial infarction: fact or artifact? J Am Coll Cardiol 49(18):1834-1840
14. Dinan T (2008) Inflammatory markers in depression. Curr Opin Psychiatr 22:32-36
15. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL (2010) A meta analysis of cytokines in major depression. Biol Psychiatry 67(5):446-57
16. Downes CE, Crack PJ (2010) Neural injury following stroke: are Toll-like receptors the link between the immune system and the CNS? Br J Pharmacol 160(8):1872-1888
17. Dunn AJ (2008) The cytokines and depression hypothesis: an update. Neuroimmune Biol 6:485-506
18. Emerich DF, Dean RL 3rd, Bartus RT (2002) The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct? Exp Neurol 173(1):168-181
19. Ferretti MT, Cuello AC (2011) Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? Curr Alzheimer Res 8(2):164-174
20. Fuller S, Steele M, Münch G (2010) Activated astroglia during chronic inflammation in Alzheimer's disease-do they neglect their neurosupportive roles? Mutat Res 690(1-2):40-49
21. Gattaz WF, Abrahao AL, Foccaccia R (2004) Childhood meningitis, brain maturation and the risk of schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:23-26
22. Glassman AH, Miller GE (2007) Where there is depression, there is inflammation sometimes! Biol Psychiatry 62:280-281
23. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, Yirmiya R (2008) Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 13(7):717-728
24. Griffiths M, Neal JW, Gasque P (2007) Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins. Int Rev Neurobiol 82:29-55
25. Hanson DR, Gottesman II (2005) Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 6:7
26. Heneka MT (2006) Inflammation in Alzheimer's disease. J Clin Neurosci Res 6:247-260
27. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8(4): 382-397
28. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71:171-186
29. Huang Y, Henry CJ, Dantzer R, Johnson RW, Godbout JP (2008) Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebro-ventricular lipopolysaccharide. Neurobiol Aging 29(11): 1744-1753
30. Iadecola C, Anrather J (2011) The immunology of stroke: from mechanisms to translation. Nat Med 17(7):796-808
31. Jin R, Yang G, Li G (2010) Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 87(5):779-789
32. Keeley P, Creed F, Tomenson B, Todd C, Borglin G, Dickens C (2008) Psychosocial predictors of health-related quality of life and health service utilisation in people with chronic low back pain. Pain 135(1-2):142-150
33. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of microglia. Physiol Rev 91(2):461-553
34. Khandelwal PJ, Herman AM, Moussa CE (2011) Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol 238(1-2):1-11
35. Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, Dasgupta S, Barral PM, Hedvat M, Diaz P, Reed JC, Stebbins JL, Pellecchia M, Sarkar D, Fisher PB (2011) Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol 226(10):2484-2493
36. Körschenhausen DA, Hampel HJ, Ackenheil M, Penning R, Müller N (1996) Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr Res 19(2-3):103-109
37. Lucas SM, Rothwell NJ, Gibson RM (2006) The role of inflammation in CNS injury and disease. Br J Pharmacol 147(Suppl 1):S232-S240
38. Machado A, Herrera AJ, Venero JL, Santiago M, De Pablos RM, Villarán RF, Espinosa-Oliva AM, Argüelles S, Sarmiento M, Delgado-Cortés MJ, Mauriño R, Cano J (2011) Peripheral inflammation increases the damage in animal models of nigro-striatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. Parkinsons Dis 2011:0393769
39. Markiewicz I, Lukomska B (2006) The role of astrocytes in the physiology and pathology of the central nervous system. Acta Neurobiol Exp (Wars) 66(4):343-358
40. Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732-741
41. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebro-spinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 211(1):13-16
42. Müller N (2010) COX-2 inhibitors as antidepressants and antipsy-chotics: clinical evidence. Curr Opin Invest Drugs 11:31-42
43. Müller N, Schwarz MJ (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12:988-1000
44. Müller N, Schwarz MJ (2008) A psychoneuroimmunological perspective to Emil Kraepelins dichotomy. Schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci 258((Suppl. 2)):97-106
45. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, Gruber R, Riedel M (2004a) COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 254(1):14-22
46. Müller N, Riedel M, Dehning S, Spellmann I, Müller-Arends A, Cerovecki A et al (2004b) Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease? Neuro-psychopharmacology 29:176
47. Müller N, Riedel M, Schwarz MJ, Engel RR (2005) Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 255(2):149-151
48. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleind-ienst N, Möller HJ, Arolt V, Riedel M (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11(7):680-684
49. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344(13):961-966
50. Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Cytokines in Parkinson's disease. J Neural Transm Suppl 58:143-151
51. Palin K, Bluthé RM, McCusker RH, Moos F, Dantzer R, Kelley KW (2007) TNFalpha-induced sickness behavior in mice with functional 55 kD TNF receptors is blocked by central IGF-I. J Neuroimmunol 187(1-2):55-60
52. Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegener-ative disease. Nat Rev Neurol 6(4):193-201
53. Raedler TJ (2011) Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 24:519-525
54. Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27:24-31
55. Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119-145
56. Rook GA, Lowry CA (2008) The hygiene hypothesis and psychiatric disorders. Trends Immunol 29:150-158
57. Sharpley CF, Agnew LL (2011) Cytokines and depression: findings, issues, and treatment implications. Rev Neurosci 22:295-302
58. Skaper SD (2007) The brain as a target for inflammatory processes and neuroprotective strategies. Ann N Y Acad Sci 1122:23-34
59. Smith JA, Das A, Ray SK, Banik NL (2012) Role of pro-inflammatory cytokines released from microglia in neurodegen-erative diseases. Brain Res Bull 87:10-20
60. Sofroniew MV (2005) Reactive astrocytes in neural repair and protection. Neuroscientist 11(5):400-407
61. Stone EA, Lin Y, Quartermain D (2008) A final common pathway for depression? Progress toward a general conceptual framework. Neurosci Biobehav Rev 32:508-524
62. Streit WJ, Mrak RE, Griffin WS (2004) Microglia and neuroinflam-mation: a pathological perspective. J Neuroinflammation 30:14
63. Wang DD, Bordey A (2008) The astrocyte odyssey. Prog Neurobiol 86(4):342-367
64. Wang Q, Tang XN, Yenari MA (2007) The inflammatory response in stroke. J Neuroimmunol 184(1-2):53-68
65. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P (2011) Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci USA 108(22):9262-9267
66. Wee YV (2010) Inflammation in neurological disorders: a help or a hindrance? Neuroscientist 16(4):408-420
67. WHO (2001) Cross-national comparisons of the prevalences and correlates of mental disorders, WHO international consortium in psychiatric epidemiology. World Health Organ 78:413-426
68. Wood PL (1995) Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. Neurol Res 17(4):242-248
69. Yang Y, Rosenberg GA (2011) Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 42(11):3323-3328
70. Zhao Y, Rempe DA (2010) Targeting astrocytes for stroke therapy. Neurotherapeutics 7(4):439-451